EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC-Reference-Cited by-同舟云学术

EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCLC

Published:2022-01 Issue:1 Volume:23 Page:60-71
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Hirsch Fred R.,Redman Mary W.,Moon James,Agustoni Francesco^ORCID,Herbst Roy S.,Semrad Thomas J.,Varella-Garcia Marileila,Rivard Chris J.,Kelly Karen,Gandara David R.,Mack Philip C.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference25 articles.

1. A randomized, phase III study of carboplatin /paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small-cell lung cancer: SWOG S0819;Herbst;Lancet,2018

2. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819;Redman;Clin Cancer Res,2012

3. Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced non-small-cell lung cancer: Southwest Oncology Group Study S0342;Herbst;J ClinOncol,2010

4. Phase II trial of carboplatin, paclitaxel, cetuximab and bevacizumab followed by cetuximab and bevacizumab in advanced non-squamous non-small-cell lung cancer SWOG S0536;Kim;J ThoracOncol,2013

5. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;J ClinOncol,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rediscovering immunohistochemistry in lung cancer;Critical Reviews in Oncology/Hematology;2024-08

2. Pathways and targeting avenues of BRAF in non-small cell lung cancer;Expert Opinion on Therapeutic Targets;2024-07-02

3. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review;Cancers;2024-06-26

4. Combined treatment with cetuximab and STA9090 has synergistic anticancer effects on human non-small cell lung cancer;Acta Biochimica et Biophysica Sinica;2024-05-30

5. The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer;Cancer Treatment Reviews;2024-01